Drugs / Bucillamine
Bucillamine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02942420 | May 2017 → Mar 2018 | cystinuria | Revive Therapeutics, Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02330796 | Apr → Nov 2015 | gout | Revive Therapeutics, Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00716248 | Jan 2007 → Dec 2011 | rheumatoid arthritis | Saitama Medical University | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT04504734 Comparator | Nov 2020 → Jun 2023 | COVID-19 | Revive Therapeutics, Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03660059 Background | Sep 2018 → Apr 2021 | rheumatoid arthritis | Astellas Pharma Inc | Completed | Met primary |
| Phase 3 | NCT02373202 Background | Feb 2015 → Nov 2016 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bucillamine | “hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod.” NCT03660059 ↗ |
| Known as | Bucilamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL80830 ↗ |
| Known as | Bucilant | ChEMBL registry synonym — accepted as the source's own label CHEMBL80830 ↗ |
| Modality | Small molecule | — CHEMBL80830 ↗ |
| Route | Oral | “Route of administration: Oral” NCT02373202 ↗ |